MedMira Stock

MedMira FCF Margin

The Free Cash Flow Margin of MedMira (MIR.V) as of Aug 13, 2026 is -1,310.94 %. In the previous year, Free Cash Flow Margin was -892.23 % — a change of 46.93% (lower).

FCF Margin

-1,310.94 %

YoY

46.93%

Last updated:

Free Cash Flow Margin of MedMira is 2026 -1,310.94 % . Free Cash Flow Margin of MedMira was 2025 -892.23 % . It decreases by 46.93% lower compared to the previous year.
Access this data via the Eulerpool API

MedMira Stock analysis

What does MedMira do? MedMira Inc. is a Canadian company specializing in the development and marketing of innovative diagnostic products. It was founded in 1993 and is headquartered in Halifax, Nova Scotia. MedMira initially focused on HIV testing and developed the first rapid test kits, which proved to be highly effective and reliable. The company later expanded its product line to include diagnostics for Hepatitis and Syphilis. MedMira has become a leading provider of rapid test kits for infectious diseases, with its products being sold globally and proven to be reliable and effective in numerous studies. The company is constantly seeking new technologies and methods to expand its offerings and provide better solutions to its customers. MedMira's business model revolves around the development and marketing of diagnostic products for the medical and pharmaceutical markets. The company collaborates with leading companies and institutions in the industry to develop new products and improve existing solutions. MedMira has different divisions focused on its various diagnostic products, such as HIV, Hepatitis, and Syphilis. Each division has a dedicated team of experts focused on developing and marketing solutions tailored to meet customer needs. The company offers a wide range of products tailored to the needs of different customers and markets, including rapid test kits, ELISA kits, and other diagnostic tools. It specializes in serving specific target groups, such as pregnant women or newborns, and constantly strives to deliver better results to its customers. One example of a product from MedMira is the Reveal G4 Combo Rapid HIV-Syphilis Test, a highly accurate rapid test that detects both HIV and Syphilis infections. The test can be conducted quickly and provides results comparable to traditional tests. MedMira prides itself on being an innovative company focused on customer needs and constantly seeking new ways to improve diagnostics. It has built an excellent reputation and enjoys the trust of leading companies and institutions in the medical and pharmaceutical sectors. MedMira is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MedMira stock

Free Cash Flow Margin of MedMira is -1,310.94 % in 2026.

Free Cash Flow Margin of MedMira changed from -892.23 % to -1,310.94 %, representing a 46.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin MedMira since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's MedMira with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

Margins — MedMira

All Key Metrics — MedMira